Ruxolitinib for Lymphoma
Trial Summary
Will I have to stop taking my current medications?
The trial requires that any previous systemic anti-cancer therapy for T-cell lymphoma must be stopped at least 2 weeks before starting the study drug. However, glucocorticoids (a type of steroid) can be used to control symptoms if reduced to 20mg or less, and topical steroids for skin conditions are allowed.
What data supports the effectiveness of the drug Ruxolitinib for treating lymphoma?
Ruxolitinib, a drug that blocks certain proteins involved in cell growth, has shown some activity in treating relapsed or hard-to-treat Hodgkin lymphoma, with a small percentage of patients experiencing partial responses. While its effects were short-lived, it was generally well-tolerated, suggesting it might be useful when combined with other treatments.12345
Is Ruxolitinib generally safe for humans?
Ruxolitinib has been studied for safety in various conditions, showing some side effects like skin reactions and anemia (low red blood cell count), but it is generally considered safe for use in humans. In animal studies, it did not increase cancer risk, and in a study with Japanese patients, most completed treatment without serious issues.678910
How is the drug Ruxolitinib unique for treating lymphoma?
Ruxolitinib is unique because it is an oral drug that inhibits Janus kinases (JAK) 1 and 2, which are involved in the signaling pathways that can contribute to cancer growth. This mechanism of action is different from many traditional chemotherapy treatments, which often target rapidly dividing cells more broadly.27111213
What is the purpose of this trial?
The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink.
Research Team
Alison Moskowitz, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
Adults with relapsed or refractory T or NK cell lymphoma who've had at least one prior systemic therapy can join this trial. They must have measurable disease, adequate blood counts, and organ function. Those with HIV may participate if treated and without active infections. Pregnant women, individuals in poor health, or those on certain other treatments are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ruxolitinib 20mg BID orally on 28-day cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Ruxolitinib
Ruxolitinib is already approved in United States, European Union for the following indications:
- Intermediate or high-risk myelofibrosis
- Polycythemia vera
- Steroid-refractory acute graft-versus-host disease
- Chronic graft-versus-host disease
- Vitiligo
- Intermediate or high-risk myelofibrosis
- Polycythemia vera
- Steroid-refractory acute graft-versus-host disease
- Chronic graft-versus-host disease
- Non-segmental vitiligo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Cornell University
Collaborator
Dana-Farber Cancer Institute
Collaborator
Thomas Jefferson University
Collaborator